For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: September 21–25, 2026
Innovation watch FDA approves the first treatment for Sanfilippo syndrome. On September 17, the FDA approved Ultragenyx’s Fayuvi, a one-time…
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
Search Posts
Op-Eds
Stockholm Syndrome
The Stockholm Convention on Persistent Organic Pollutants (POPs) is a United Nations Environment Programme Convention, which bans or regulates industrial chemicals and pesticides. The…
Op-Eds
Brussels’ Bad Science Will Cost the World Dear
Regulatory officials in the European Union seem to be ignorant of the rule of holes: when you are in one, stop digging. Numerous analyses…
Op-Eds
The Brundtland Legacy
The five-year tenure of Gro Harlem Brundtland as head of the World Health Organisation (WHO) has just come to an end. She leaves behind…
Op-Eds
Los Beneficios de la Biotecnologa
Click on pdf link above to obtain full article…
Op-Eds
The Benefits of Biotech
Click pdf link above for full text of article Ever since the publication of Rachel Carson’s…
USA Today